The immunomodulator ammonium trichloro(dioxyethy1ene-0-0')tellurate (AS101) has previously been found by us t o have radioprotective properties when injected into mice before sublethal and lethal doses of irradiation. ASlOl also was found t o protect mice from hematopoietic damage caused by various chemotherapeutic drugs. Based on these findings, phase I 1 clinical trials with cancer patients treated with AS101, in combination with chemotherapy, are currently underway. In the present study, we wanted t o assess the role of several cytokines in the radioprotection conferred by AS101. We show that the administration of neutralizing antibodies against interleukin-l (IL-l) receptor, IL-6 receptor, IL-6, tumor necrosis factor (TNF), or stem cell factor (SCF) completely abrogates the a b i l i of ASlOl t o increase the survival of lethally irradiated mice. Moreover, the injection HEMICAL-OR RADIATION-induced septicemia and death are primarily because of damage of the intestine and hematopoietic system. This treatment invariably leads to a decrease in BM function of variable durations that is reflected in a substantial decrease in mature blood elements.'.' In the past few years, various substances that protect the hemopoietic system against adverse effects of cytoreductive treatments have been described. Radioprotectors are either chemical or biologic agents, the administration of which before or during irradiation diminishes radiation-induced damage. The chemical agents are primarily thiol compounds3 that are known to act by scavenging free radicals. The biologic agents are immunomodulatory and/or inflammatory substances, many of which induce the release of cytokine^.^.^ The most effective and most extensively studied radioprotective cytokines are interleukin-1 (IL-1): tumor necrosis factor a ( T N F~) ,~ granulocyte colony-stimulating factor (G-CSF): and granulocyte-macrophage CSF (GM-CSF)." Recently, treatment with recombinant stem cell factor (rSCF) has also been shown to protect mice from lethal effects of irradiation." SCF has been shown to act on very primitive cell populations that have been described as stem cell populations." The immunomodulator AS 101, ammonium trichloro(dioxoethy1ene-0-0') tellurate, was developed in Bar Ilan University and previously shown by us to stimulate the production of a variety of cytokines.13"' Phase I clinical trials on cancer patients showed an enhancement in the secretion of endogenous TNF, interferon (IFN), and IL-L '~,~~ More recently, ASlOl has been shown to have radioprotective properties when injected into mice before sublethal and lethal doses of irradiati~n.~'~'~'~ In addition, ASlOl was found to protect mice from hemopoietic damages caused by sublethal doses of cyclophosphamide (CYP) and to increase the rate of survival of mice treated with lethal doses of CYP." Moreover, ASlOl was shown to protect bone marrow (BM) progenitor cells and BM stromal cells from toxic effects of the CYP derivative ASTA-Z 7557.'3*24 In all these studies, ASlOl prevented damage caused both to BM progenitor cells and to their functions as well as to lymphoid cell reactivity. As a result of these studies, phase I1 clinical trials with cancer patients treated with AS 101 in combination with chemotherapy have been initiated. of each of these antibodies reduces the ability of ASlOl t o increase the number of BM, spleen cells, and the number of circulating neutrophils, lymphocytes, and platelets in irradiated mice. In addition, these antibodies abrogate the enhancing effect of ASlOl on the secretion of IL-3, IL-6, and granulocyte-macrophage colony-stimulating factor, all of which decrease significantly in sublethally irradiated mice. By contrast, the injection of anti-IL-2 receptor antibody or control Igs t o AS101-treated mice does not interfere with the radioprotective effects of the compound. These results suggest a role for 11-1, IL-6, TNFa, and SCF in the radioprotective effect of AS101. Because cytokine toxicity remains a significant concern, the clinical application of AS101, which has no toxicity, is particularly valuable. 0 1995 by The American Society of Hematology.
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In this study, we assessed the relative contribution of various hematopoietic growth factors to the radioprotection confered by ASlOl, by using neutralizing antibodies to various cytokines. The results suggest that IL-l, IL-6, TNFa, and the c-kit ligand play an important role in the effect of ASlOl against lethal and sublethal effects of radiation.
MATERIALS AND METHODS

Mice
Balbk mice, 2 months of age, were purchased from Jackson Laboratories (Bar Harbor, Maine) and were housed 10 per cage.
Treatment With A N 0 1 ASlOl (Ossirene; Baker Norton Pharmaceuticals Inc, Miami, FL) was administered to mice at a concentration of 10 pdO.2 mL per injection. The compound was supplied in a solution of phosphatebuffered saline (PBS) at pH 7.4 and maintained at 4°C. Before use, ASlOl was diluted in PBS, and the appropriate concentration in 0.2-mL volume was administered to mice by intraperitoneal injection. Control animals received 0.2 mL PBS at the same time.
Antibodies
Antibodies used for injection were rat monoclonal IgGz antimouse L -1 receptor (IL-1R Genzyme, Boston, MA) and the control purified rat IgG,; rat monoclonal IgG, antimouse IL-6R (Biosource, Camarillo, CA). Rat IgG, monoclonal antimurine IL-6 was purchased from Biosource. Monoclonal IgG, rat antimouse TNF was purchased from Pharmingen (San Diego, CA). Control rat IgG, Ig (Pharmingen). Monoclonal IgG antimouse IL-2R was purchased from Biodesign (Kennebunk, ME), and the monoclonal rat IgGz antimouse SCF was from Genzyme.
Treatment With Antibodies
Antibodies diluted in 0.1 mL PBS were injected into mice simultaneously with ASlOl 24 hours before irradiation. Control mice were injected with either the respective control Ig or with the antibody alone 24 hours before irradiation. All neutralizing antibodies and their respective control Igs were injected at 100 pglmouse, except for anti-IL-6 antibodies that were injected at 600 pg/mouse and anti-SCF antibodies that were injected at 50 pg/mouse.
Recovery of BM and Spleen Cells
Femurs and spleens were removed and placed in PBS. Single-cell suspensions of BM were prepared by washing each cavity of the femur with 5 mL PBS with a sterile syringe and a 26-gauge needle. Spleen cells were passed through stainless steel mesh nets, treated with hypotonic solution to lyse erythrocytes, and washed 3 times. Cell counts were obtained using a hemocytometer. Viability, as assessed by trypan-blue exclusion method, was always found to be more than 95%.
Induction of Cytokines Secretion In Vitro
Splenocytes (5 X 1O6/mL for GM-CSF secretion and 1 X IO"/mL for IL-3 and IL-6 secretion) suspended in enriched RPMI-1640 culture medium supplemented with 10% fetal calf serum were seeded in 24-well culture plates in the presence of 2.5 pg/mL concanavalin A (ConA; Biomaker, Rehovot, Israel). The cultures were incubated for 24 hours at 37°C. Supernatants were collected and stored at 4°C.
Quanti$cation of Cytokines
The IL-3-responsive (GM-CSF-unresponsive) cell line 32 DCI-23 was used to assay IL-3 content. 32DCI-23 cells (IO4 per well) were seeded in triplicate in culture medium with or without dilutions of the supernatant fraction. After 48 hours, 'H-thymidine ("H-TdR) uptake was determined in a liquid scintillation counter. One unit of 1L-3 activity was defined as the reciprocal log 2 dilution required to give 50% of the maximal proliferation of IO4 IL-3-dependent 32 DCI-23 cells after 48 hours of culture. IL-6 and GM-CSF were quantified using murine IL-6 or murine GM-CSF enzyme-linked immunoassay kit (Endogen, Boston, MA).
Radiation
Mice were exposed to y-irradiation and received total irradiation from a cesium-l37 radiation source at a dose rate of 450 cGy/ min. For survival analysis, mice were irradiated with 750 cGy. For sublethal irradiation, mice were irradiated with 450 cGy.
Statistical Analysis
For multiple group comparisons, the pairwise I-test was used. Survival curves were tested both by comparing the cumulative percentage of survival and by the percentage of survival at the termination of the experiment. For the first method, we used the Gehan-Wilcoxon test, and, for the second, we used the x* test for proportions.
RESULTS
The Effect of Cytokine Abrogation on Radioprotection Conferred by AS101
Effect on survival of lethally irradiated mice.
We have previously shown that pretreatment of mice with ASlOl con- Eflect on spleen cell and BM cellularity. In the following set of experiments, mice were irradiated with sublethal doses of irradiation (450 cGy). At this dose of irradiation, ASlOl has previously been shown to protect various cellular functions at different time points after irradiation." For the purpose of studying the effect of neutralizing antibodies against various cytokines on the radioprotective effect of AS 101, day 5 after irradiation was selected. Figures 2A and B show that, after subjection to a sublethal dose of irradiation, there was evidence of an earlier recovery of spleen and BM cellularity in mice injected with AS101 before irradiation. Five days after 450 cGy of irradiation, the number of spleen cells in PBS-injected mice was less than 10% of normal, and the number of BM cells was 14% of normal nonirradiated mice. These values increased to nearly normal levels in mice pretreated with AS101 . AS 101 (10 pg/mouse) increased the number of BM cells from 4.1 t 0.8 to 27.5 -t 3.1 X 10"/2 femurs ( P < .01) and increased the number of spleen cells from 7.5 ? 0.6 to 125 5 7.5 X lO'/spleen ( P < .()I). Treatment of mice with anti-IL-1R antibodies nearly abrogated the increase in spleen and BM cellularity in ASlOl-treated mice. The number of BM and spleen cells in AS 10 1 -injected and irradiated mice was not significantly different from that of nonirradiated mice (Fig 2) . Similar results were obtained when mice were treated with anti-IL-6R, anti-TNF, or anti-SCF antibodies. However, no abrogation of the increase in BM and spleen cellularity in AS101-treated mice was observed when anti-IL-2R antibodies or the control relevant Igs were used.
Effect on cytokines secretion. Preliminary studies in our laboratory showed that the secretion of GM-CSF, IL-6, and IL-3 by spleen cells of irradiated mice is significantly decreased as early as 24 hours after irradiation (data not shown). Pretreatment with ASlOl 24 hours before sublethal irradiation restores the ability of spleen cells to secrete, in the presence of ConA, all three cytokines as examined at various time points after irradiation.
Five days after irradiation, a significant ( P < .01) decrease in the secretion of several cytokines including GM-CSF, IL-6, and IL-3 was observed. (Figs 3 through 5) . Treatment with AS 101 increased the level of IL-3 and IL-6 to levels that were indistinguishable from those observed in nonirradiated mice. The level of GM-CSF was also significantly increased. Pretreatment of mice with each of the anticytokine antibodies (except anti-IL-2R antibody) significantly decreased IL-3, GM-CSF, and IL-6 levels in ASIOl-treated animals AS101 ( P < .01).
Role of specific cytokines in the hematopoietic recovey conferred I~v ASIOI. To study the role of cytokines in AS I0 I -induced hematopoietic recovery, mice were sublethally irradiated and injected with ASlOl in combination with one of the various neutralizing antibodies. Although mice irradiated with 450 cGy survived for 7 months, there was a marked effect on peripheral blood hematology. Five days after irradiation the number of white blood cells decreased from 5.4 -t 0.44 to 0.59 t-0.03 X IO'/pL. The number of platelets decreased from 805 2 28 to 538.5 2 24.5 X 103/pL and that of neutrophils decreased from 1.09 +-0.14 to 0.1 t-0.01 X IO'/pL. The number of lymphocytes was also significantly decreased. As can be seen in Table  I , the hematopoietic recovery in AS101-treated mice was complete 5 days after irradiation. This recovery was totally abrogated when any of the four antibodies (IL-IR, IL-6R. TNF, and SCF) were injected to mice treated with AS101 ( P < .01 for all antibodies). In contrast, control Igs did not significantly affect the AS 101-induced hematopoietic recovery (data not shown).
DISCUSSION
The data presented in this study clearly show a significant role for specific cytokines in the radioprotective effect of the immunomodulator AS 101. The results indicate that AS I01 -induced endogenous production of four cytokines (IL-l, TNF, IL-6, and SCF) is required for hematopoietic recovery and for the survival of mice subjected to sublethal or lethal irradiation.
We have recently shown that radioprotection conferred by
For personal use only. on December 27, 2017. by guest www.bloodjournal.org From ASlOl is associated with induction of progenitor cells to enter into S phase,I7." which is known to be the most radioresistant phase of the cell cycle." Also, AS101 enhanced the stimulation of spleen colony-forming units (CFU-S) toward proliferation and CFU-S self-renewal." Moreover, we showed that the DNA repair processes expressing the cellular responses associated with the restoration of the normal nucleotide sequence after damage caused to the DNA were also significantly increased after treatment with AS 101 Early progenitor cells have been previously reported to be relatively more resistant to various DNA-damaging agents.".*' This resistance is likely to result from a more efficient repair mechanism. Therefore, it is quite possible that AS101 accounts for the faster rate of DNA repair by For Results represent mean f SE of 18 mice per group (PBS, AS101, control nonirradiated) and 6 mice per group (neutralizing antibodies). *, P < .01 increase versus PBS; #, P < .01 decrease versus AS101. (Kalechman et al, unpublished results) . Some of the above-mentioned cytokines have been previously reported to protect mice if injected, either alone or in combination, before irradiation. For example, IL-l has been reported to radioprotect mice when administered 20 hours before irradiation.' IL-l and TNFa have been reported to have an additive effect in radioprotection? and the c-kit ligand has been recently reported to protect mice from lethal effects of radiation." The injection of IL-6 by itself did not improve radiation survival; however, IL-6 has been shown to act synergistically with suboptimal doses of IL-l to enhance survival from lethal irradiation.*"
ASlOl in vitro
Because ASlOl was able to simultaneously induce the production of a variety of radioprotective cytokines, it was hypothesized that this agent might protect mice from the toxic effect of irradiation by enhancing secretion of these factors.
The availability of neutralizing antibodies to cytokines or their receptors allowed the assessment of the contribution of the individual cytokines to radioprotection by ASlOl. Neutralizing antibodies were injected simultaneously with 1559 ASIOI, because our aim was to treat mice with these antibodies 16 to 20 hours before the increase in endogenous cytokine production induced by ASlOl occurred.
It is of interest to note that, although ASlOl stimulates simultaneously a variety of cytokines, injection of one of neutralizing antibodies to IL-IR, IL-6R, TNF-a, or SCF completely reduces the protective effect of ASIOI. These results suggest that radioprotection by ASlOl can be conferred only with increased secretion of all four cytokines. However, these may induce yet another unknown factor that confers the radioprotection.
The interdependence and synergistic interactions of these four cytokines is well documented. Several studies suggested that many of the actions of IL-I or TNF, including stimulation of production of acute-phase proteins by hepatocytes,3".3' stimulation of the hypothalmic-pituitary adrenal axis," or hematopoietin-l" effects, can be mimicked by ILIn addition, SCF has been reported to act as a potent comitogen for hematopoietic stem cells in combination with IL-6, IL-3, and IL-I . 36 The absolute requirement of a variety of cytokines for hematopoietic recovery from lethal irradiation has been previously reported. The administration of IL-6 antibody blocked IL-1 -and TNF-induced radioprotect i~n .~' In addition, antibodies to IL-IR abrogated TNF-induced radioprotection.3x Recently, the neutralization of SCF has been shown to reduce the survival of irradiated mice treated with the radioprotectants lipopolysaccharide and IL-I .l<)
The observation that cytokines are more effective in combination rather than when administered separately lends further support to the notion that these agents act in concert and that, despite their apparent redundency, they all must be present for normal host defense. The ability of AS IO1 to induce the secretion of a variety of cytokines suggests that it is able to accelerate the restoration of functional hemopoietic cells, because the administration of each of these factors stimulates a broader spectrum of progenitor cells than anticipated. For example, high doses of GM-CSF stimulated multipotential (CFU-granulocyte-erythroid-macrophage-megakaryocyte) and erythroid (CFU-E and burst-forming unit E) progenitor cells in addition to the expected myelogenous cells?" Thus, interaction of the different mediators may be required for increased hematopoiesis. Moreover, the induction of endogenous cytokines is more effective than their exogenous administration. Vogel et all' have reported that 6.34.35 For personal use only. on December 27, 2017. by guest www.bloodjournal.org From after intraperitoneal administration of a single dose of rIL-1, high titers (2 to 3 X lo7 U/mL) of CSF appeared in the circulation within 2 hours and persisted for up to 6 hours. This level is higher than CSF concentration achieved after intraperitoneal administration of 20,000 U of GM-CSF.
It is important to note that the elevation in cytokine production increased threefold to sixfold in irradiated mice as compared with irradiated antibody-treated mice, despite the equal number of spleen cells in the ConA-stimulated cultures of both groups. This is probably because of the protection of T-cell functions rather than the protection of mature CD4' cell numbers. This explanation rests on the previously reported capability of AS101 to protect the ability of spleen cells of irradiated mice, in which no decrease in the proportion of CD4' cells occurred, to proliferate and secrete IL- 2.20 In summary, the present study shows that endogenous production of IL-1, IL-6, TNF, and kit ligand in mice injected with AS101 provides a major contribution to radioprotection by this agent. The data suggest that the simultaneous production of all four cytokines by AS101 is a prerequisite for its protection from radiation lethality. The possibility that these relatively toxic cytokines can be replaced by the nontoxic immunomodulator presents an obvious clinical advantage.
A better understanding of the mechanism by which ASlOl confers radioprotection will enable us to use AS101 more effectively for the restoration of hemopoiesis in patients after radiation therapy or in those suffering from overdose or accidental irradiation.
